Literature DB >> 635471

Circulating immune complexes, complement activation kinetics and serum sickness following treatment with heterologous anti-snake venom globulin.

H Nielsen, H Sørensen, V Faber, S E Svehag.   

Abstract

Consecutive serum and plasma samples, from a patient receiving 100 ml polyvalent horse anti-venom globulin after a rattlesnake bite, were analysed for circulating immune complexes (IC) and activation of complement factors. IC were determined by two independent methods, a complement consumption assay and a Clq-binding assay. Rapidly rising levels of complement-fixing circulating IC were detected as early as 4--5 days after the serum treatment and distinct IC-activity was recorded in both assays on day 8 when clinical symptoms of serum sickness were observed. The IC remained in circulation for at least 5 weeks. Signs of intravascular C-activation in the form of low C3, C4 and C5 values was noted on day 1 after treatment. Factor B was demonstrable 3--4 days after the snake bite and this factor and C3c attained a peak around day 8, just before maximal suppression of native C3 and C4. 14 days after the globulin treatment C3c and B were declining rapidly while C3 and C4 approached normal values first 36 days after treatment. An increase in heterophilic antibodies to sheep erythrocytes was observed after treatment with anti-venom globulin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 635471     DOI: 10.1111/j.1365-3083.1978.tb00423.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

1.  Complement activation profiles in disease.

Authors:  D L Brown
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

2.  Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites.

Authors:  P Malasit; D A Warrell; P Chanthavanich; C Viravan; J Mongkolsapaya; B Singhthong; C Supich
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

3.  Serial analysis of circulating immune complexes, complement, and antithymocyte globulin antibodies in heart transplant recipients.

Authors:  G D Harkiss; D L Brown; R Cory-Pearce; T A English
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

4.  A Single Dose of Viperfav(TM) May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation.

Authors:  Tihana Kurtović; Miran Brvar; Damjan Grenc; Maja Lang Balija; Igor Križaj; Beata Halassy
Journal:  Toxins (Basel)       Date:  2016-08-19       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.